InflaRx Phase 3 trial results not signif9icant in severe Covid

 

• Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo (p-value=0.094), but did not show statistical significance on the pre-specified primary endpoint

• Pre-specified sensitivity analysis of the primary endpoint results in p-values of <0.05 in three out of four planned analyses in favor of vilobelimab treatment

• 43% relative reduction in 28-day all-cause mortality detected in pre-specified subgroup analysis in Western European patients comparing vilobelimab to placebo treatment (n=209, p-value=0.014)

• Additional pre-specified subgroup analyses in patients with more severe disease confirm treatment benefit for vilobelimab, resulting in p-values of <0.05

• Company plans to discuss results with regulatory authorities

• Company to host a conference call today at 8:30 am EDT/2:30 pm CEST

Conference call scheduled for today at 8:30 am EDT/2:30 pm CET

InflaRx will host a conference call to discuss the Phase III PANAMO study results today, Thursday, March 31st at 8:30 am EDT (2:30 pm CEST). To participate in the conference call, participants may pre-register here and will receive a dedicated link and dial-in details to easily and quickly access the call. A replay of the event will be available on the InflaRx website in the Investors - Events & Presentations section

https://finance.yahoo.com/news/inflarx-announces-encouraging-phase-iii-113000670.html